406482-22-2 Usage
General Description
1-Bromo-4-methoxy-2,3-difluorobenzene is a chemical compound with the molecular formula C7H6BrF2O. It is a halogenated aromatic compound with a bromine atom, two fluorine atoms, and a methoxy group attached to a benzene ring. 1-BROMO-4-METHOXY-2,3-DIFLUOROBENZENE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used in the production of liquid crystals, dyes, and other organic compounds. Due to its halogenated nature, 1-bromo-4-methoxy-2,3-difluorobenzene should be handled with caution and proper safety measures to prevent exposure and potential health hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 406482-22-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,6,4,8 and 2 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 406482-22:
(8*4)+(7*0)+(6*6)+(5*4)+(4*8)+(3*2)+(2*2)+(1*2)=132
132 % 10 = 2
So 406482-22-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H5BrF2O/c1-11-5-3-2-4(8)6(9)7(5)10/h2-3H,1H3
406482-22-2Relevant articles and documents
FUSED PENTACYCLIC ANTI - PROLIFERATION COMPOUNDS
-
Page/Page column 78, (2013/02/28)
The present invention relates to novel compounds of formula (I) wherein X, Q, R1, R2, R3, R4, R5, R6, R7, R8, R21, R22 and R23 are as defined herein. The compounds of formula (I) are inhibitors of telomerase enzyme function and are accordingly useful for the treatment cellular proliferation disorders, such as cancer
NOVEL ESTROGEN RECEPTOR LIGANDS
-
Page/Page column 65, (2009/03/07)
The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are as defined in the specification. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.